Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:acquisitionYear |
2015
|
| gptkbp:address |
30 Enterprise, Suite 400, Aliso Viejo, CA 92656, USA
|
| gptkbp:ceased_operations |
2015
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
central nervous system disorders
|
| gptkbp:founded |
1988
|
| gptkbp:founder |
Keith Katkin
|
| gptkbp:headquarters_location |
gptkb:Aliso_Viejo,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avanir Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notable_executive |
Gregory T. Flesher
Keith Katkin Rohan Palekar |
| gptkbp:notableProduct |
gptkb:Nuedexta
Onzetra Xsail |
| gptkbp:parentCompany |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:product_indication |
gptkb:pseudobulbar_affect
migraine |
| gptkbp:regulates |
gptkb:FDA
|
| gptkbp:stockSymbol |
AVNR
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.avanir.com/
|
| gptkbp:bfsParent |
gptkb:dextromethorphan/quinidine
|
| gptkbp:bfsLayer |
7
|